BioSpace News Archive

Hackensack Meridian Health commits $400 million investment in Englewood Health

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced a proposed public offering of up to $150 million of shares of its common stock

CMS continues to deny Medicare beneficiaries with chronic kidney disease full access to this innovative therapy

The A&R Preliminary Prospectus and Registration Statement are subject to completion and amendment.

Genomma Lab cordially invites you to join its quarterly conference call to discuss results for the third quarter of 2019.

Principia Biopharma Inc. announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $28.00 per share.

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics, clinical lab, and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal fourth quarter and year ended July 31, 2019.

Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) (the “Company” or “Valens”), a vertically integrated provider of industry leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab is pleased to report its financial results for the third quarter of fiscal 2019.

Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced FDA’s approval to initiate Denovo’s Phase 2b clinical study of DB102 in patients with newly-diagnosed glioblastoma (GBM) in combination with radiation and temozolomide.

Natera, Inc., a global leader in cell-free DNA testing, announced the launch of a proposed follow-on public offering of $175,000,000 of shares of its common stock.